Personalized Decision Support Research Articles

Personalized decision support system for tailoring IgA nephropathy treatment strategies

BackgroundThe ongoing debate surrounding the use of immunosuppressive treatments for IgA nephropathy (IgAN) underscores the demand for personalized and effective strategies. MethodsAnalyzed data from 807 IgAN patients over 5+ years using three methods: Random Forest with molecular biomarkers, network biomarkers with graph engineering, and an auto-encoder model. All models were trained using identical demographic, clinical, and pathological data, employing an 80–20 split for training and testing purposes. ResultsIn the comprehensive assessment of IgAN prognosis, the Random Forest model, employing molecular biomarkers, demonstrated strong performance metrics (AUC = 0.83, sensitivity = 0.51, specificity = 0.96). However, traditional graph feature engineering on patient-specific networks outperformed these results with an AUC of 0.90, sensitivity of 0.64, and specificity of 0.94. The Auto-encoder model showed the best accuracy (AUC = 0.91, sensitivity = 0.46, specificity = 0.96). The findings highlighted the superior predictive capabilities of network biomarkers over molecular biomarkers for adverse renal outcome prediction in IgAN. Consequently, we integrated Auto-encoder-derived Network Biomarkers with Random Forest Models to enhance prognostic precision in diverse IgAN treatment scenarios. The prediction for the prognosis of patients receiving supportive care, glucocorticoid therapy, and immunosuppressant treatment yielded AUC values of 0.95, 0.96, and 1, respectively, indicating high specificity. Drawing from these insights, we pioneered the development of an innovative decision support model for IgAN treatment. This model demonstrated the ability to make medical decisions comparable to those by experienced nephrologists, enabling the customization of personalized disease management strategies. ConclusionOur system accurately predicted IgAN prognosis and evaluated various treatment efficacies, aiding physicians in devising optimal therapeutic strategies for patients.

A text analytics approach for mining public discussions in online cancer forum: Analysis of multi-intent lung cancer treatment dataset

BackgroundOnline cancer forums (OCF) are increasingly popular platforms for patients and caregivers to discuss, seek information on, and share opinions about diseases and treatments. This interaction generates a substantial amount of unstructured text data, necessitating deeper exploration. Using time series data, our study exploits topic modeling in the novel domain of online cancer forums (OCFs) to identify meaningful topics and changing dynamics of online discussion across different lung cancer treatment intent groups. MethodsFor this purpose, a dataset comprising 27,998 forum posts about lung cancer was collected from three OCFs: lungcancer.net, lungevity.org, and reddit.com, spanning the years 2016 to 2018. ResultsThe analysis reflects the public discussion on multi-intent lung cancer treatment over time, taking into account seasonal variations. Discussions on cancer symptoms and prevention garnered the most attention, dominating both curative and palliative care discussions. There were distinct seasonal peaks: curative care topics surged from winter to late spring, while palliative care topics peaked from late summer to mid-autumn. Keyword analysis highlighted that lung cancer diagnosis and treatment were primary topics, whereas cancer prevention and treatment outcomes were predominant across multi-care contexts. For the study period, curative care discussions predominantly revolved around informational support and disease syndromes. In contrast, social support and cancer prevention prevailed in the palliative care context. Notably, topics such as cancer screening and cancer treatment exhibit pronounced seasonal variations in curative care, peaking in frequency during the summers (May to August) of the study period. Meanwhile, the topic of tumor control within palliative care showed significant seasonal influence during the winters and summers of 2017 and 2018. ConclusionOur text analysis approach using OCF data shows potential for computational methods in this novel domain to gain insights into trends in public cancer communication and seasonal variations for a better understanding of improving personalized care, decision support, treatment outcomes, and quality of life.

Dynamic Prognosis Prediction for Patients on DAPT After Drug-Eluting Stent Implantation: Model Development and Validation.

The rapid evolution of artificial intelligence (AI) in conjunction with recent updates in dual antiplatelet therapy (DAPT) management guidelines emphasizes the necessity for innovative models to predict ischemic or bleeding events after drug-eluting stent implantation. Leveraging AI for dynamic prediction has the potential to revolutionize risk stratification and provide personalized decision support for DAPT management. We developed and validated a new AI-based pipeline using retrospective data of drug-eluting stent-treated patients, sourced from the Cerner Health Facts data set (n=98 236) and Optum's de-identified Clinformatics Data Mart Database (n=9978). The 36 months following drug-eluting stent implantation were designated as our primary forecasting interval, further segmented into 6 sequential prediction windows. We evaluated 5 distinct AI algorithms for their precision in predicting ischemic and bleeding risks. Model discriminative accuracy was assessed using the area under the receiver operating characteristic curve, among other metrics. The weighted light gradient boosting machine stood out as the preeminent model, thus earning its place as our AI-DAPT model. The AI-DAPT demonstrated peak accuracy in the 30 to 36 months window, charting an area under the receiver operating characteristic curve of 90% [95% CI, 88%-92%] for ischemia and 84% [95% CI, 82%-87%] for bleeding predictions. Our AI-DAPT excels in formulating iterative, refined dynamic predictions by assimilating ongoing updates from patients' clinical profiles, holding value as a novel smart clinical tool to facilitate optimal DAPT duration management with high accuracy and adaptability.

Utilizing RoBERTa Model for Churn Prediction through Clustered Contextual Conversation Opinion Mining

In computational study and automatic recognition of opinions in free texts, certain words in sentences are used to decide its sentiments. While analysing each customer’s opinion per time in churn management will be effective for personalised recommendations. Oftentimes, the opinion is not sufficient for contextualised content mining. While personalised recommendations are time consuming, it also does not provide complete picture of an overall sentiment in the business community of customers. To help businesses identify widespread issues affecting a large segment of their customers towards engendering patterns and trends of different customer churn behaviour, here, we developed a clustered contextualised conversation as opinions set for integration with Roberta Model. The developed churn behavioural opinion clusters disambiguated short messages while charactering contents collectively based on context beyond keyword-based sentiment matching for effective mining. Based on the predicted opinion threshold, customer churn category for group-based personalised decision support was generated, with matching concepts. The baseline RoBERTa model on the contextually clustered opinions, trained with a batch size of 16, a learning rate of 2e-5, over 8 epochs, using a maximum sequence length of 128 and standard hyperparameters, achieved an accuracy of 92%, Precision of 88%, Recall of 86% and F1 score of 84% over a test set of 30%.

Semantic Integration of BPMN Models and FHIR Data to Enable Personalized Decision Support for Malignant Melanoma

With digital patient data increasing due to new diagnostic methods and technology, showing the right data in the context of decision support at the point of care becomes an even greater challenge. Standard operating procedures (SOPs) modeled in BPMN (Business Process Model and Notation) contain evidence-based treatment guidance for all phases of a certain diagnosis, while physicians need the parts relevant to a specific patient at a specific point in the clinical process. Therefore, integration of patient data from electronic health records (EHRs) providing context to clinicians is needed, which is stored and communicated in HL7 (Health Level Seven) FHIR (Fast Healthcare Interoperability Resources). To address this issue, we propose a method combining an integration of stored data into BPMN and a loss-free transformation from BPMN into FHIR, and vice versa. Based on that method, an identification of the next necessary decision point in a specific patient context is possible. We verified the method for treatment of malignant melanoma by using an extract of a formalized SOP document with predefined decision points and validated FHIR references with real EHR data. The patient data could be stored and integrated into the BPMN element ‘DataStoreReference’. Our loss-free transformation process therefore is the foundation for combining evidence-based knowledge from formalized clinical guidelines or SOPs and patient data from EHRs stored in FHIR. Processing the SOP with the available patient data can then lead to the next upcoming decision point, which will be displayed to the physician integrated with the corresponding data.

Revolutionizing Patient Care: A Comprehensive Review of Artificial Intelligence Applications in Anesthesia.

This review explores the intersection of artificial intelligence (AI) and anesthesia, examining its transformative impact on patient care across various phases. Beginning with a historical overview of anesthesia, we highlight the critical role of technological advancements in ensuring optimal patient outcomes. The emergence of AI in healthcare sets the stage for a comprehensive analysis of its applications in anesthesia. In the preoperative phase, AI facilitates personalized risk assessments and decision support, optimizing anesthesia planning and drug dosage predictions. Moving to the intraoperative phase, we delve into AI's role in monitoring and control through sophisticated anesthesia monitoring and closed-loop systems. Additionally, we discuss the integration of robotics and AI-guided procedures, revolutionizing surgical assistance. Transitioning to the postoperative phase, we explore AI-driven postoperative monitoring, predictive analysis for complications, and the integration of AI into rehabilitation programs and long-term follow-up. These new applications redefine patient recovery, emphasizing personalized care and proactive interventions. However, the integration of AI in anesthesia poses challenges and ethical considerations. Data security, interpretability, and bias in AI algorithms demand scrutiny. Moreover, the evolving patient-doctor relationship in an AI-driven care landscape requires a delicate balance between efficiency and human touch. Looking forward, we discuss the future directions of AI in anesthesia, anticipating advances in technology and AI algorithms. The integration of AI into routine clinical practice and its potential impact on anesthesia education and training are explored, emphasizing the need for collaboration, education, and ethical guidelines. This review provides a comprehensive overview of AI applications in anesthesia, offering insights into the present landscape, challenges, and future directions. The synthesis of historical perspectives, current applications, and future possibilities underscores the transformative potential of AI in revolutionizing patient care within the dynamic field of anesthesia.

From E-Commerce to Virtual Commerce: The Exciting Opportunities of Virtual Shopping

Abstract Virtual commerce has the potential to transform the shopping experience. It is highly interactive and can create immersive experiences when consumers wear head-mounted displays. Benefits include increased telepresence, better size and proportion judgement, customizable shopping environments, highly personalized decision support and social interaction opportunities. Technological advances in VR hardware, such as improved display resolution and reduced motion sickness, contribute to a more seamless and enjoyable shopping experience. These benefits can lead to higher purchase rates. However, there are also privacy concerns due to the many ways in which data can be collected. While the future of VR shopping is difficult to predict, AR applications are already well established. Tech giants, research institutions, and startups will play a critical role in shaping the future of virtual commerce.

Personalized Federated Learning for Institutional Prediction Model using Electronic Health Records: A Covariate Adjustment Approach.

Federated learning (FL) has attracted attention as a technology that allows multiple medical institutions to collaborate on AI without disclosing each other's patient data. However, FL has the challenge of being unable to robustly learn when the data of participating clients is non-independently and non-identically distributed (Non-IID). Personalized Federated Learning (PFL), which constructs a personalized model for each client, has been proposed as a solution to this problem. However, conventional PFL methods do not ensure the interpretability of personalization, specifically, the identification of which data samples are contributed to each personalized learning, which is important for AI in medical applications. In this study, we propose a novel PFL framework, Federated Adjustment of Covariate (FedCov), which acquires a propensity score model representing the covariate shift among clients through prior FL, then learns a final model by weighting the contribution of each training sample to PFL based on the estimated propensity score. This approach enables both the learning of personalized models through covariate adjustment and the visualization of the contribution of each client to PFL. FedCov was evaluated in the prediction of in-hospital mortality across 50 hospitals in the eICU Collaborative Research Database, achieving an ROC-AUC of 0.750. This result outperformed the AUCs in the 0.720-0.735 range achieved by conventional FL methods and was closest to the AUC of 0.754 achieved by centralized learning.Clinical Relevance- This study demonstrates the feasibility of providing sophisticated and personalized AI-driven clinical decision support to any medical institution through personalized federated learning.

Deep learning model to predict exercise stress test results: Optimizing the diagnostic test selection strategy and reduce wastage in suspected coronary artery disease patients

BackgroundCardiac exercise stress testing (EST) offers a non-invasive way in the management of patients with suspected coronary artery disease (CAD). However, up to 30% EST results are either inconclusive or non-diagnostic, which results in significant resource wastage. Our aim was to build machine learning (ML) based models, using patients demographic (age, sex) and pre-test clinical information (reason for performing test, medications, blood pressure, heart rate, and resting electrocardiogram), capable of predicting EST results beforehand including those with inconclusive or non-diagnostic results. MethodsA total of 30,710 patients (mean age 54.0 years, 69% male) were included in the study with 25% randomly sampled in the test set, and the remaining samples were split into a train and validation set with a ratio of 9:1. We constructed different ML models from pre-test variables and compared their discriminant power using the area under the receiver operating characteristic curve (AUC). ResultsA network of Oblivious Decision Trees provided the best discriminant power (AUC=0.83, sensitivity=69%, specificity=0.78%) for predicting inconclusive EST results. A total of 2010 inconclusive ESTs were correctly identified in the testing set. ConclusionsOur ML model, developed using demographic and pre-test clinical information, can accurately predict EST results and could be used to identify patients with inconclusive or non-diagnostic results beforehand. Our system could thus be used as a personalised decision support tool by clinicians for optimizing the diagnostic test selection strategy for CAD patients and to reduce healthcare expenditure by reducing nondiagnostic or inconclusive ESTs.

Predicting favorable response to intravenous morphine in pediatric critically ill cardiac patients.

Analgesia and sedation are integral to the care of critically ill children. However, the choice and dose of the analgesic or sedative drug is often empiric, and models predicting favorable responses are lacking. We aimed to compute models to predict a patient's response to intravenous morphine. We retrospectively analyzed data from consecutive patients admitted to the Cardiac Intensive Care Unit (January 2011-January 2020) who received at least one intravenous bolus of morphine. The primary outcome was a decrease in the State Behavioral Scale (SBS) ≥1 point; the secondary outcome was a decrease in the heart rate Z-score (zHR) at 30 min. Effective doses were modeled using logistic regression, Lasso regression, and random forest modeling. A total of 117,495 administrations of intravenous morphine among 8140 patients (median age 0.6 years [interquartile range [IQR] 0.19, 3.3]) were included. The median morphine dose was 0.051 mg/kg (IQR 0.048, 0.099) and the median 30-day cumulative dose was 2.2 mg/kg (IQR 0.4, 15.3). SBS decreased following 30% of doses, did not change following 45%, and increased following 25%. The zHR significantly decreased after morphine administration (median delta-zHR -0.34 [IQR-1.03, 0.00], p < 0.001). The following factors were associated with favorable response to morphine: A concomitant infusion of propofol, higher prior 30-day cumulative dose, being invasively ventilated and/or on vasopressors. Higher morphine dose, higher zHR pre-morphine, an additional analgosedation bolus ±30 min around the index bolus, a concomitant ketamine or dexmedetomidine infusion, and showing signs of withdrawal syndrome were associated with unfavorable response. Logistic regression (area under the receiver operating characteristic [ROC] curve [AUC] 0.900) and machine learning models (AUC 0.906) performed comparably, with a sensitivity of 95%, specificity of 71%, and negative predictive value of 97%. Statistical models identify 95% of effective intravenous morphine doses in pediatric critically ill cardiac patients, while incorrectly suggesting an effective dose in 29% of cases. This work represents an important step toward computer-aided, personalized clinical decision support tool for sedation and analgesia in ICU patients.

Digitizing local search: An empirical analysis of mobile search behavior in offline shopping

Mobile devices have become increasingly prevalent in the context of consumers' offline search and shopping behavior by acting as personal decision support tools. This paper investigates the relationship between consumers' real-time location and their search behavior when shopping offline. We develop two location-specific measures based on mobile device usage to analyze the association between a consumer's real-time location and their search behavior: Present store distance and present store density. We apply these measures to a unique dataset from a leading mobile product information app that includes >13 million search sessions from 2.5 million consumers searching for 1.8 million different products. Our findings show that store distance and store density significantly influence consumers' mobile search behavior: detailed searches for product-specific attributes (search depth) increase as store distance decreases and store density increases, while the number of jointly searched products within the same category (search breadth) increases as store distance and density increase. We also find that durable products weaken the main effects of store distance and density on search depth but strengthen it for search breadth. These results provide insights for offline retailers to better understand location-specific consumer demands and improve their mobile in-app targeting and product assortment decisions.

QuantImage v2: a comprehensive and integrated physician-centered cloud platform for radiomics and machine learning research

BackgroundRadiomics, the field of image-based computational medical biomarker research, has experienced rapid growth over the past decade due to its potential to revolutionize the development of personalized decision support models. However, despite its research momentum and important advances toward methodological standardization, the translation of radiomics prediction models into clinical practice only progresses slowly. The lack of physicians leading the development of radiomics models and insufficient integration of radiomics tools in the clinical workflow contributes to this slow uptake.MethodsWe propose a physician-centered vision of radiomics research and derive minimal functional requirements for radiomics research software to support this vision. Free-to-access radiomics tools and frameworks were reviewed to identify best practices and reveal the shortcomings of existing software solutions to optimally support physician-driven radiomics research in a clinical environment.ResultsSupport for user-friendly development and evaluation of radiomics prediction models via machine learning was found to be missing in most tools. QuantImage v2 (QI2) was designed and implemented to address these shortcomings. QI2 relies on well-established existing tools and open-source libraries to realize and concretely demonstrate the potential of a one-stop tool for physician-driven radiomics research. It provides web-based access to cohort management, feature extraction, and visualization and supports “no-code” development and evaluation of machine learning models against patient-specific outcome data.ConclusionsQI2 fills a gap in the radiomics software landscape by enabling “no-code” radiomics research, including model validation, in a clinical environment. Further information about QI2, a public instance of the system, and its source code is available at https://medgift.github.io/quantimage-v2-info/.Key pointsAs domain experts, physicians play a key role in the development of radiomics models.Existing software solutions do not support physician-driven research optimally.QuantImage v2 implements a physician-centered vision for radiomics research.QuantImage v2 is a web-based, “no-code” radiomics research platform.

Partially observable collaborative model for optimizing personalized treatment selection

Precision medicine that enables personalized treatment decision support has become an increasingly important research topic in chronic disease care. The main challenges in designing a treatment algorithm include modeling individual disease progression dynamics and designing adaptive treatment selection strategy. This study aims to develop an adaptive treatment selection framework tailored to an individual patient’s disease progression pattern and treatment response. We propose a Partially Observable Collaborative Model (POCM) to capture the individual variations in a heterogeneous population and optimize treatment outcomes in three stages. The POCM first infers the disease progression models by subgroup patterns using population data in stage one and then fine-tunes the models for individual patients with a small number of treatment trials in stage two. In stage three, we show how the treatment policies based on the Partially Observable Markov Decision Process (POMDP) can be tailored to individual patients by utilizing the disease models learned from the POCM. Using a simulated population of chronic depression patients, we show that the POCM can more accurately estimate the personal disease progression than the traditional method of solving a hidden Markov model. We also compare the POMDP treatment policies with other heuristic policies and demonstrate that the POCM-based policies give the highest net monetary benefits in majority of parameter settings. To conclude, the POCM method is a promising approach to model the chronic disease progression process and recommend a personalized treatment plan for individual patients in a heterogeneous population.

Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.

The utility of routine extensive molecular profiling of pediatric tumors is a matter of debate due to the high number of genetic alterations of unknown significance or low evidence and the lack of standardized and personalized decision support methods. Digital drug assignment (DDA) is a novel computational method to prioritize treatment options by aggregating numerous evidence-based associations between multiple drivers, targets, and targeted agents. DDA has been validated to improve personalized treatment decisions based on the outcome data of adult patients treated in the SHIVA01 clinical trial. The aim of this study was to evaluate the utility of DDA in pediatric oncology. Between 2017 and 2020, 103 high-risk pediatric cancer patients (< 21years) were involved in our precision oncology program, and samples from 100 patients were eligible for further analysis. Tissue or blood samples were analyzed by whole-exome (WES) or targeted panel sequencing and other molecular diagnostic modalities and processed by a software system using the DDA algorithm for therapeutic decision support. Finally, a molecular tumor board (MTB) evaluated the results to provide therapy recommendations. Of the 100 cases with comprehensive molecular diagnostic data, 88 yielded WES and 12 panel sequencing results. DDA identified matching off-label targeted treatment options (actionability) in 72/100 cases (72%), while 57/100 (57%) showed potential drug resistance. Actionability reached 88% (29/33) by 2020 due to the continuous updates of the evidence database. MTB approved the clinical use of a DDA-top-listed treatment in 56 of 72 actionable cases (78%). The approved therapies had significantly higher aggregated evidence levels (AELs) than dismissed therapies. Filtering of WES results for targeted panels missed important mutations affecting therapy selection. DDA is a promising approach to overcome challenges associated with the interpretation of extensive molecular profiling in the routine care of high-risk pediatric cancers. Knowledgebase updates enable automatic interpretation of a continuously expanding gene set, a "virtual" panel, filtered out from genome-wide analysis to always maximize the performance of precision treatment planning.

Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study

Approximately 62% of patients with breast cancer with a pathogenic variant (BRCA1 or BRCA2) undergo primary breast-conserving therapy. The study aims to develop a personalized risk management decision support tool for carriers of a pathogenic variant (BRCA1 or BRCA2) who underwent breast-conserving therapy for unilateral early-stage breast cancer. We developed a Bayesian network model of a hypothetical cohort of carriers of BRCA1 or BRCA2 diagnosed with stage I/II unilateral breast cancer and treated with breast-conserving treatment who underwent subsequent second primary cancer risk-reducing strategies. Using event dependencies structured according to expert knowledge and conditional probabilities obtained from published evidence, we predicted the 40-year overall survival rate of different risk-reducing strategies for 144 cohorts of women defined by the type of pathogenic variants (BRCA1 or BRCA2), age at primary breast cancer diagnosis, breast cancer subtype, stage of primary breast cancer, and presence or absence of adjuvant chemotherapy. Absence of adjuvant chemotherapy was the most powerful factor that was linked to a dramatic decline in survival. There was a negligible decline in the mortality in patients with triple-negative breast cancer, who received no chemotherapy and underwent any secondary risk-reducing strategy, compared with surveillance. The potential survival benefit from any risk-reducing strategy was more modest in patients with triple-negative breast cancer who received chemotherapy compared with patients with luminal breast cancer. However, most patients with triple-negative breast cancer in stage I benefited from bilateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy or just risk-reducing salpingo-oophorectomy. Most patients with luminal stage I/II unilateral breast cancer benefited from bilateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy. The impact of risk-reducing salpingo-oophorectomy in patients with luminal breast cancer in stage I/II increased with age. Most older patients with the BRCA1 and BRCA2 pathogenic variants in exons 12-24/25 with luminal breast cancer may gain a similar survival benefit from other risk-reducing strategies or surveillance. Our study showed that it is mandatory to consider the complex interplay between the types of BRCA1 and BRCA2 pathogenic variants, age at primary breast cancer diagnosis, breast cancer subtype and stage, and received systemic treatment. As no prospective study results are available at the moment, our simulation model, which will integrate a decision support system in the near future, could facilitate the conversation between the health care provider and patient and help to weigh all the options for risk-reducing strategies leading to a more balanced decision.

Harnessing artificial intelligence to infer novel spatial biomarkers for the diagnosis of eosinophilic esophagitis.

Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus associated with elevated esophageal eosinophils. Second only to gastroesophageal reflux disease, EoE is one of the leading causes of chronic refractory dysphagia in adults and children. EoE is a clinicopathologic disorder and the histological portion of the diagnosis requires enumerating the density of esophageal eosinophils in esophageal biopsies, and evaluating additional features such as basal zone hyperplasia is helpful. However, this task requires time-consuming, somewhat subjective manual analysis, thus reducing the ability to process the complex tissue structure and infer its relationship with the patient's clinical status. Previous artificial intelligence (AI) approaches that aimed to improve histology-based diagnosis focused on recapitulating identification and quantification of the area of maximal eosinophil density, the gold standard manual metric for determining EoE disease activity. However, this metric does not account for the distribution of eosinophils or other histological features, over the whole slide image. Here, we developed an artificial intelligence platform that infers local and spatial biomarkers based on semantic segmentation of intact eosinophils and basal zone distributions. Besides the maximal density of eosinophils [referred to as Peak Eosinophil Count (PEC)] and a maximal basal zone fraction, we identify the value of two additional metrics that reflect the distribution of eosinophils and basal zone fractions. This approach enables a decision support system that predicts EoE activity and potentially classifies the histological severity of EoE patients. We utilized a cohort that includes 1,066 biopsy slides from 400 subjects to validate the system's performance and achieved a histological severity classification accuracy of 86.70%, sensitivity of 84.50%, and specificity of 90.09%. Our approach highlights the importance of systematically analyzing the distribution of biopsy features over the entire slide and paves the way toward a personalized decision support system that will assist not only in counting cells but can also potentially improve diagnosis and provide treatment prediction.

Need for numbers: assessing cancer survivors’ needs for personalized and generic statistical information

BackgroundStatistical information (e.g., on long-term survival or side effects) may be valuable for healthcare providers to share with their patients to facilitate shared decision making on treatment options. In this pre-registered study, we assessed cancer survivors’ need for generic (population-based) versus personalized (tailored towards patient/tumor characteristics) statistical information after their diagnosis. We examined how information coping style, subjective numeracy, and anxiety levels of survivors relate to these needs and identified statistical need profiles. Additionally, we qualitatively explored survivors’ considerations for (not) wanting statistical information.MethodsCancer survivors’ need for statistics regarding incidence, survival, recurrence, side effects and quality of life were assessed with an online questionnaire. For each of these topics, survivors were asked to think back to their first cancer diagnosis and to indicate their need for generic and personalized statistics on a 4-point scale (‘not at all’- ‘very much’). Associations between information coping style, subjective numeracy, and anxiety with need for generic and personalized statistics were examined with Pearson’s correlations. Statistical need profiles were identified using latent class analysis. Considerations for (not) wanting statistics were analyzed qualitatively.ResultsOverall, cancer survivors (n = 174) had a higher need for personalized than for generic statistics (p < .001, d = 0.74). Need for personalized statistics was associated with higher subjective numeracy (r = .29) and an information-seeking coping style (r = .41). Three statistical need profiles were identified (1) a strong need for both generic and personalized statistics (34%), (2) a stronger need for personalized than for generic statistics (55%), and (3) a little need for both generic and personalized statistics (11%). Considerations for wanting personalized cancer statistics ranged from feelings of being in control to making better informed decisions about treatment. Considerations for not wanting statistics related to negative experience with statistics and to the unpredictability of future events for individual patients.ConclusionsIn light of the increased possibilities for using personalized statistics in clinical practice and decision aids, it appears that most cancer survivors want personalized statistical information during treatment decision-making. Subjective numeracy and information coping style seem important factors influencing this need. We encourage further development and implementation of data-driven personalized decision support technologies in oncological care to support patients in treatment decision making.

Virtual patient framework for the testing of mechanical ventilation airway pressure and flow settings protocol

Background and ObjectiveModel-based and personalised decision support systems are emerging to guide mechanical ventilation (MV) treatment for respiratory failure patients. However, model-based treatments require resource-intensive clinical trials prior to implementation. This research presents a framework for generating virtual patients for testing model-based decision support, and direct use in MV treatment. MethodsThe virtual MV patient framework consists of 3 stages: 1) Virtual patient generation, 2) Patient-level validation, and 3) Virtual clinical trials. The virtual patients are generated from retrospective MV patient data using a clinically validated respiratory mechanics model whose respiratory parameters (respiratory elastance and resistance) capture patient-specific pulmonary conditions and responses to MV care over time. Patient-level validation compares the predicted responses from the virtual patient to their retrospective results for clinically implemented MV settings and changes to care. Patient-level validated virtual patients create a platform to conduct virtual trials, where the safety of closed-loop model-based protocols can be evaluated. ResultsThis research creates and presents a virtual patient platform of 100 virtual patients generated from retrospective data. Patient-level validation reported median errors of 3.26% for volume-control and 6.80% for pressure-control ventilation mode. A virtual trial on a model-based protocol demonstrates the potential efficacy of using virtual patients for prospective evaluation and testing of the protocol. ConclusionThe virtual patient framework shows the potential to safely and rapidly design, develop, and optimise new model-based MV decision support systems and protocols using clinically validated models and computer simulation, which could ultimately improve patient care and outcomes in MV.

Heart OBServation app: development of a decision support tool for parents of infants with severe cardiac disease.

Many parents of infants with CHD find it difficult to recognise symptoms of deterioration in their children. Therefore, a personalised decision support application for parents has been developed. This application aims to increase parents' awareness of their infant's normal condition, help them assess signs of deterioration, decide who and when to contact health services, and what to report. The aim of this paper is to describe the concept and report results from a usability study. An interprofessional group developed a mobile application called the Heart OBServation app in close collaboration with parents using an iterative process. We performed a usability study consisting of semi-structured interviews of 10 families at discharge and after one month and arranged two focus group interviews with nurses caring for these families. A thematic framework analysis of the interviews explored the usability of features in the application. Usability was assessed twice using the System Usability Scale, and a user log was registered throughout the study. The overall system usability score, 82.3 after discharge and 81.7 after one month, indicates good system usability. The features of Heart OBServation were perceived as useful to provide tailored information, increase awareness of the child's normal condition, and to guide parents in what to look for. To empower parents, an interactive discharge checklist was added. The Heart OBServation demonstrated good usability and was well received by parents and nurses. Feasibility and benefits of this application in clinical practice will be investigated in further studies.

Could Artificial Intelligence/Machine Learning and Inclusion of Diet-Gut Microbiome Interactions Improve Disease Risk Prediction? Case Study: Coronary Artery Disease.

Coronary artery disease (CAD) is the most common cardiovascular disease (CVD) and the main leading cause of morbidity and mortality worldwide, posing a huge socio-economic burden to the society and health systems. Therefore, timely and precise identification of people at high risk of CAD is urgently required. Most current CAD risk prediction approaches are based on a small number of traditional risk factors (age, sex, diabetes, LDL and HDL cholesterol, smoking, systolic blood pressure) and are incompletely predictive across all patient groups, as CAD is a multi-factorial disease with complex etiology, considered to be driven by both genetic, as well as numerous environmental/lifestyle factors. Diet is one of the modifiable factors for improving lifestyle and disease prevention. However, the current rise in obesity, type 2 diabetes (T2D) and CVD/CAD indicates that the “one-size-fits-all” approach may not be efficient, due to significant variation in inter-individual responses. Recently, the gut microbiome has emerged as a potential and previously under-explored contributor to these variations. Hence, efficient integration of dietary and gut microbiome information alongside with genetic variations and clinical data holds a great promise to improve CAD risk prediction. Nevertheless, the highly complex nature of meals combined with the huge inter-individual variability of the gut microbiome poses several Big Data analytics challenges in modeling diet-gut microbiota interactions and integrating these within CAD risk prediction approaches for the development of personalized decision support systems (DSS). In this regard, the recent re-emergence of Artificial Intelligence (AI) / Machine Learning (ML) is opening intriguing perspectives, as these approaches are able to capture large and complex matrices of data, incorporating their interactions and identifying both linear and non-linear relationships. In this Mini-Review, we consider (1) the most used AI/ML approaches and their different use cases for CAD risk prediction (2) modeling of the content, choice and impact of dietary factors on CAD risk; (3) classification of individuals by their gut microbiome composition into CAD cases vs. controls and (4) modeling of the diet-gut microbiome interactions and their impact on CAD risk. Finally, we provide an outlook for putting it all together for improved CAD risk predictions.